THE CLEARANCE AND BIOAVAILABILITY OF PAMIDRONATE IN PATIENTS WITH BREAST-CANCER AND BONE METASTASES

被引:44
作者
DALEYYATES, PT
DODWELL, DJ
PONGCHAIDECHA, M
COLEMAN, RE
HOWELL, A
机构
[1] CHRISTIE HOSP & HOLT RADIUM INST,DEPT MED ONCOL,MANCHESTER M20 9BX,LANCS,ENGLAND
[2] WESTERN GEN HOSP,MED ONCOL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND
关键词
PAMIDRONATE; APD; PHARMACOKINETICS; BIOAVAILABILITY; CLEARANCE; BREAST CANCER;
D O I
10.1007/BF02555856
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The pharmacokinetics and bioavailability of pamidronate were assessed in patients with breast cancer, 6 subjects received the drug intravenously and 7 orally. The initial plasma half-life of pamidronate was short (42 +/- 27 min) and the apparent total plasma clearance was high (471 +/- 298 ml/min). The renal clearance (74 +/- 34 ml/min) was similar to the creatinine clearance (66 +/- 19 ml/min). Most of the renal elimination occurred during and immediately post a 4 h infusion of the drug (23.2 +/- 7.9% in 24 h). The non-renal clearance was ascribed to uptake by bone and deep tissue compartments. Little additional drug appeared in the urine after 24 h. The mean bioavailability was estimated using a parallel study design to be 0.3% for a 300 mg oral dose.
引用
收藏
页码:433 / 435
页数:3
相关论文
共 12 条
[1]   TREATMENT OF PAGETS-DISEASE OF BONE [J].
CANTRILL, JA ;
ANDERSON, DC .
CLINICAL ENDOCRINOLOGY, 1990, 32 (04) :507-518
[2]  
CANTWELL MJ, 1987, BRIT MED J, V294, P467
[3]   CLODRONATE KINETICS AND DYNAMICS [J].
CONRAD, KA ;
LEE, SM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (01) :114-120
[4]   ASSAY OF 1-HYDROXY-3-AMINOPROPYLIDENE-1,1-BISPHOSPHONATE AND RELATED BISPHOSPHONATES IN HUMAN-URINE AND PLASMA BY HIGH-PERFORMANCE ION CHROMATOGRAPHY [J].
DALEYYATES, PT ;
GIFFORD, LA ;
HOGGARTH, CR .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1989, 490 (02) :329-338
[5]   A COMPARISON OF THE PHARMACOKINETICS OF C-14-LABELED APD AND TC-99M-LABELED APD IN THE MOUSE [J].
DALEYYATES, PT ;
BENNETT, R .
CALCIFIED TISSUE INTERNATIONAL, 1988, 43 (02) :125-127
[6]   REDUCTION IN CALCIUM EXCRETION IN WOMEN WITH BREAST-CANCER AND BONE METASTASES USING THE ORAL BISPHOSPHONATE PAMIDRONATE [J].
DODWELL, DJ ;
HOWELL, A ;
FORD, J .
BRITISH JOURNAL OF CANCER, 1990, 61 (01) :123-125
[7]   ABSORPTION OF ORAL DIPHOSPHONATE IN NORMAL SUBJECTS [J].
FOGELMAN, I ;
SMITH, L ;
MAZESS, R ;
WILSON, MA ;
BEVAN, JA .
CLINICAL ENDOCRINOLOGY, 1986, 24 (01) :57-62
[8]  
HOGGARTH CR, IN PRESS CALCIF TISS
[9]   INTESTINAL-ABSORPTION OF DISODIUM ETHANE-1-HYDROXY-1,1-DIPHOSPHONATE (DISODIUM ETIDRONATE) USING A DECONVOLUTION TECHNIQUE [J].
RECKER, RR ;
SAVILLE, PD .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1973, 24 (04) :580-589
[10]  
ROWLAND M, 1989, CLIN PHARMACOKINET, P541